Published in Eur Radiol on September 30, 2008
ESUR prostate MR guidelines 2012. Eur Radiol (2012) 8.86
Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol (2009) 1.76
Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur Radiol (2013) 1.60
Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol (2009) 1.18
Imaging of prostate cancer local recurrences: why and how? Eur Radiol (2009) 1.14
Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer. Eur Radiol (2010) 1.12
Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging. Curr Urol Rep (2010) 1.11
Multiparametric magnetic resonance imaging of prostate cancer. Indian J Radiol Imaging (2012) 1.09
Detection of local recurrent prostate cancer after radical prostatectomy in terms of salvage radiotherapy using dynamic contrast enhanced-MRI without endorectal coil. Radiat Oncol (2012) 1.07
Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. J Cancer (2014) 1.04
Pitfalls in Interpreting mp-MRI of the Prostate: A Pictorial Review with Pathologic Correlation. Insights Imaging (2015) 0.91
Multiparametric MRI for recurrent prostate cancer post radical prostatectomy and postradiation therapy. Biomed Res Int (2014) 0.89
Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU). World J Urol (2011) 0.88
The incremental value of contrast-enhanced MRI in the detection of biopsy-proven local recurrence of prostate cancer after radical prostatectomy: effect of reader experience. AJR Am J Roentgenol (2012) 0.87
PET/MR in prostate cancer: technical aspects and potential diagnostic value. Eur J Nucl Med Mol Imaging (2013) 0.86
Magnetic resonance-ultrasound fusion prostate biopsy in the diagnosis of prostate cancer. Urol Oncol (2016) 0.84
Functional and molecular imaging of localized and recurrent prostate cancer. Eur J Nucl Med Mol Imaging (2013) 0.83
Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide? Urol Oncol (2016) 0.80
Recent advances in magnetic resonance imaging of prostate cancer. F1000 Med Rep (2010) 0.79
Pelvic MRI findings in relapsed prostate cancer after radical prostatectomy. Radiat Oncol (2015) 0.78
The clinical role of multimodality imaging in the detection of prostate cancer recurrence after radical prostatectomy and radiation therapy: past, present, and future. Ecancermedicalscience (2015) 0.78
Evaluation of 3 T pelvic MRI imaging in prostate cancer patients receiving post-prostatectomy IMRT. World J Urol (2014) 0.77
Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy? Eur J Nucl Med Mol Imaging (2014) 0.77
Early dynamic imaging in (68)Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions. Eur J Nucl Med Mol Imaging (2016) 0.77
Rationale and development of image-guided intensity-modulated radiotherapy post-prostatectomy: the present standard of care? Cancer Manag Res (2015) 0.76
Advanced imaging for the early diagnosis of local recurrence prostate cancer after radical prostatectomy. Biomed Res Int (2014) 0.76
Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer. J Clin Imaging Sci (2016) 0.76
Controversies on individualized prostate cancer care: gaps in current practice. Ther Adv Urol (2013) 0.76
MRI in prostate cancer. Iran Red Crescent Med J (2013) 0.75
Salvage high-dose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy. J Contemp Brachytherapy (2016) 0.75
Diffusion-weighted magnetic resonance diagnosis of local recurrences of prostate cancer after radical prostatectomy: preliminary evaluation on twenty-seven cases. Biomed Res Int (2014) 0.75
Detection of prostate cancer local recurrence following radical prostatectomy: assessment using a continuously acquired radial golden-angle compressed sensing acquisition. Abdom Radiol (2017) 0.75
Dynamic contrast-enhanced MRI for automatic detection of foci of residual or recurrent disease after prostatectomy. Strahlenther Onkol (2016) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol (1999) 4.78
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet (1997) 3.84
Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol (1999) 3.19
Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol (2007) 3.02
Changes in prostate cancer incidence and treatment in USA. Lancet (1994) 3.01
Epidemiology of prostate cancer. Urology (2003) 2.91
[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging (2006) 2.63
Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol (2001) 2.15
Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology (2004) 2.13
Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol (1994) 2.10
Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol (2000) 1.89
Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology (2003) 1.84
[11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging (2007) 1.84
Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology (1994) 1.64
5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol (1994) 1.51
Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol (2006) 1.49
11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol (2003) 1.34
The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol (1994) 1.29
Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology (2001) 1.21
Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int (2007) 1.18
Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol (1998) 1.16
Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology (2003) 1.15
Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging (2002) 1.15
Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin (2003) 1.14
MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol (1997) 1.08
The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. J Urol (2005) 1.05
Diagnosis of local recurrence after radical prostatectomy. BJU Int (2004) 0.91
Computed tomographic detection of pelvic and inguinal lymph-node metastases from primary and recurrent pelvic malignant disease. Radiology (1980) 0.89
Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology (2000) 0.88
Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol (1997) 0.85
11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging. Urol Int (2005) 0.84
Re: Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst (2001) 0.84
Value of transrectal ultrasound in identifying local disease after radical prostatectomy. Urology (1993) 0.77
The use of transrectal ultrasound in the detection and evaluation of local pelvic recurrences after a radical urological pelvic operation. J Urol (1990) 0.76
Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound. J Urol (1992) 0.75
Sonographic characteristics of the urethrovesical anastomosis in the early post-radical prostatectomy patient. J Urol (1992) 0.75
The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol (1993) 0.75
Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol (2008) 3.55
Does tumor growth follow a "universal law"? J Theor Biol (2003) 2.47
Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst (2011) 2.47
Measured versus estimated total liver volume to preoperatively assess the adequacy of the future liver remnant: which method should we use? Ann Surg (2013) 2.39
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol (2012) 2.36
Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol (2004) 1.90
Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods. Med Care (2012) 1.82
Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist (2012) 1.79
Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat (2004) 1.62
Food groups and renal cell carcinoma: a case-control study from Italy. Int J Cancer (2007) 1.60
Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol (2006) 1.45
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One (2011) 1.44
Postoperative liver dysfunction and future remnant liver: where is the limit? Results of a prospective study. World J Surg (2007) 1.43
Alcohol drinking and pancreatic cancer risk: a meta-analysis of the dose-risk relation. Int J Cancer (2010) 1.34
Coffee drinking and endometrial cancer risk: a metaanalysis of observational studies. Am J Obstet Gynecol (2008) 1.32
Portal vein ligation as an efficient method of increasing the future liver remnant volume in the surgical treatment of colorectal metastases. Arch Surg (2008) 1.32
Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf (2011) 1.21
Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur Urol (2010) 1.20
The second ESGAR consensus statement on CT colonography. Eur Radiol (2012) 1.16
Alcohol drinking and esophageal squamous cell carcinoma with focus on light-drinkers and never-smokers: a systematic review and meta-analysis. Int J Cancer (2011) 1.12
Percutaneous vertebroplasty and bone cement leakage: clinical experience with a new high-viscosity bone cement and delivery system for vertebral augmentation in benign and malignant compression fractures. Cardiovasc Intervent Radiol (2008) 1.11
Correlations between diffusion-weighted imaging and breast cancer biomarkers. Eur Radiol (2012) 1.10
Pain relief following percutaneous vertebroplasty: results of a series of 283 consecutive patients treated in a single institution. Cardiovasc Intervent Radiol (2007) 1.10
Emptying the rectum before treatment delivery limits the variations of rectal dose - volume parameters during 3DCRT of prostate cancer. Radiother Oncol (2006) 1.08
Quality indicators in radiotherapy. Radiother Oncol (2007) 1.08
Statins and primary liver cancer: a meta-analysis of observational studies. Eur J Cancer Prev (2013) 1.07
Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multicenter observational study. Radiother Oncol (2009) 1.06
EU-ADR healthcare database network vs. spontaneous reporting system database: preliminary comparison of signal detection. Stud Health Technol Inform (2011) 1.06
A meta-analysis of alcohol drinking and oral and pharyngeal cancers. Part 2: results by subsites. Oral Oncol (2010) 1.05
Micronutrients and the risk of renal cell cancer: a case-control study from Italy. Int J Cancer (2007) 1.05
A meta-analysis of alcohol drinking and oral and pharyngeal cancers. Part 1: overall results and dose-risk relation. Oral Oncol (2010) 1.04
Extension of right portal vein embolization to segment IV portal branches. Arch Surg (2005) 1.03
Alcohol drinking and laryngeal cancer: overall and dose-risk relation--a systematic review and meta-analysis. Oral Oncol (2010) 1.01
Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. Sci Rep (2015) 0.99
Random-effects meta-regression models for studying nonlinear dose-response relationship, with an application to alcohol and esophageal squamous cell carcinoma. Stat Med (2010) 0.99
Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer. Eur Radiol (2006) 0.99
Temperature measurement during polymerization of bone cement in percutaneous vertebroplasty: an in vivo study in humans. Cardiovasc Intervent Radiol (2009) 0.98
Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study. Int J Radiat Oncol Biol Phys (2005) 0.98
Food groups and endometrial cancer risk: a case-control study from Italy. Am J Obstet Gynecol (2008) 0.96
The American Society for Gastrointestinal Endoscopy (ASGE) diagnostic algorithm for obscure gastrointestinal bleeding: eight burning questions from everyday clinical practice. Dig Liver Dis (2012) 0.96
Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism. Cancer Res (2003) 0.96
Treatment of extraspinal painful bone metastases with percutaneous cementoplasty: a prospective study of 50 patients. Cardiovasc Intervent Radiol (2008) 0.94
Minimally invasive treatment of C2 odontoid traumatic fracture with transoral percutaneous vertebroplasty. Eur Radiol (2006) 0.92
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int (2012) 0.92
Clinical indications for computed tomographic colonography: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline. Eur Radiol (2015) 0.92
Magnetic resonance imaging and Orbscan assessment of the anterior chamber. J Cataract Refract Surg (2005) 0.91
Alcohol consumption and prostate cancer risk: a meta-analysis of the dose-risk relation. Eur J Cancer Prev (2012) 0.91
Adverse events of computed tomography colonography: an Italian National Survey. Dig Liver Dis (2013) 0.90
Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal carcinoma. Cancer Chemother Pharmacol (2010) 0.90
Treatment of painful compression vertebral fractures with vertebroplasty: results and complications. Radiol Med (2005) 0.90
Osteonecrosis of the jaw after zoledronic acid and denosumab treatment. J Clin Oncol (2011) 0.90
Comparison of three different iodine-based bowel regimens for CT colonography. Eur Radiol (2009) 0.90
Accessibility as a major determinant of radiotherapy underutilization: a population based study. Health Policy (2006) 0.90
Percutaneous vertebral augmentation assisted by PEEK implant in painful osteolytic vertebral metastasis involving the vertebral wall: experience on 40 patients. Pain Physician (2013) 0.90
Alcohol drinking and epithelial ovarian cancer risk. a systematic review and meta-analysis. Gynecol Oncol (2012) 0.89
Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis. Curr Drug Saf (2007) 0.89
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. Ann Surg Oncol (2014) 0.89
Drug-induced acute myocardial infarction: identifying 'prime suspects' from electronic healthcare records-based surveillance system. PLoS One (2013) 0.88
Surgery and radiotherapy in the treatment of malignant parotid tumors: a retrospective multicenter study. Tumori (2009) 0.88
Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma. Med Oncol (2003) 0.88
Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. Expert Rev Anticancer Ther (2012) 0.88
Percutaneous vertebroplasty in multiple myeloma: prospective long-term follow-up in 106 consecutive patients. Cardiovasc Intervent Radiol (2011) 0.87
CT colonography: role of a second reader CAD paradigm in the initial training of radiologists. Eur J Radiol (2010) 0.87
Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome. Int J Radiat Oncol Biol Phys (2011) 0.87
Laparotomy wound recurrence of endometrial carcinoma. Gynecol Oncol (2003) 0.87
Signal detection of potentially drug-induced acute liver injury in children using a multi-country healthcare database network. Drug Saf (2014) 0.86
An automatic method for colon segmentation in CT colonography. Comput Med Imaging Graph (2009) 0.86
Improving sun-protection behavior among children: results of a cluster-randomized trial in Italian elementary schools. The "SoleSi SoleNo-GISED" Project. J Invest Dermatol (2007) 0.86
Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer. Eur Radiol (2005) 0.86
Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis. Clin Drug Investig (2011) 0.85
A fully automatic algorithm for segmentation of the breasts in DCE-MR images. Conf Proc IEEE Eng Med Biol Soc (2010) 0.85
A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy. Oncol Lett (2012) 0.85
Clinical and biological prognostic factors in 179 cases with sinonasal carcinoma treated in the Italian Piedmont region. Oncology (2009) 0.85
Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. J Hypertens (2014) 0.85
Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era. J Neurooncol (2011) 0.85
Chondrosarcoma of the nasal septum. Eur Arch Otorhinolaryngol (2014) 0.84
Percutaneous vertebroplasty in osteoporotic patients: an institutional experience of 1,634 patients with long-term follow-up. J Vasc Interv Radiol (2011) 0.84
Aspirin and risk of renal cell cancer in Italy. Eur J Cancer Prev (2010) 0.84
Performance of a fully automatic lesion detection system for breast DCE-MRI. J Magn Reson Imaging (2011) 0.83
External beam radiotherapy plus high-dose-rate brachytherapy for treatment of locally advanced prostate cancer: the initial experience of the Catalan Institute of Oncology. Brachytherapy (2009) 0.83
Increasing the risk of late rectal bleeding after high-dose radiotherapy for prostate cancer: the case of previous abdominal surgery. Results from a prospective trial. Radiother Oncol (2012) 0.83
CT colonography interpretation times: effect of reader experience, fatigue, and scan findings in a multi-centre setting. Eur Radiol (2006) 0.83
Staging of colorectal liver metastases after preoperative chemotherapy. Diffusion-weighted imaging in combination with Gd-EOB-DTPA MRI sequences increases sensitivity and diagnostic accuracy. Eur Radiol (2012) 0.83
Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke. J Hypertens (2016) 0.83
Virtual endoscopy of laryngeal carcinoma: is it useful? Otolaryngol Head Neck Surg (2005) 0.82
Polyp measurement and size categorisation by CT colonography: effect of observer experience in a multi-centre setting. Eur Radiol (2006) 0.82
Impact of the radiotherapy technique on the correlation between dose-volume histograms of the bladder wall defined on MRI imaging and dose-volume/surface histograms in prostate cancer patients. Phys Med Biol (2013) 0.82
Vertebral augmentation with nitinol endoprosthesis: clinical experience in 40 patients with 1-year follow-up. Cardiovasc Intervent Radiol (2013) 0.82
Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART). Med Oncol (2013) 0.81
Clinical and technical feasibility of ultra-boost irradiation in Dominant Intraprostatic Lesion by Tomotherapy: preliminary experience and revision of literature. Panminerva Med (2015) 0.81